Hoplite Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Hoplite Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-551,310	Closed	-$77.5M	–	32
2015 Q4	$77.5M	Hold	551,310	–	–	3.36%	15
2015 Q3	$73.2M	Sell	551,310 -289,656	-34%	-$49.9M	2.77%	18
2015 Q2	$148M	Hold	840,966	–	–	3.96%	9
2015 Q1	$145M	Buy	840,966 +99,026	+13%	+$17M	4.48%	9
2014 Q4	$121M	Buy	741,940 +104,232	+16%	+$17.3M	3.36%	14
2014 Q3	$102M	Buy	637,708 +122,998	+24%	+$18.9M	2.61%	21
2014 Q2	$75.7M	Sell	514,710 -238,347	-32%	-$33.1M	1.95%	24
2014 Q1	$104M	Sell	753,057 -331,247	-31%	-$49.9M	2.88%	17
2013 Q4	$137M	Buy	+1,084,304	New	+$112M	3.86%	6

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Hoplite Capital Management's JAZZ Position: Q1 2016 in Review

Hoplite Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2016, closing a stake of 551,310 shares — an estimated $77.5M sold.

Hoplite Capital Management first reported a position in JAZZ in Q4 2013 and held it in 9 quarters. The position peaked at $148M in Q2 2015. 339 funds tracked by Wall St. Rank hold JAZZ as of Q1 2016.

Hoplite Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Hoplite Capital Management sold 551,310 Jazz Pharmaceuticals shares in Q1 2016, an estimated $77.5M.
Hoplite Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 9 quarters.
Hoplite Capital Management's Jazz Pharmaceuticals position peaked at $148M in Q2 2015.
339 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2016.

Based on Hoplite Capital Management's 13F filing for Q1 2016, filed 16 May 2016.